Castle Biosciences, Inc.
CSTL
$24.06
$0.502.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 346.27M | 347.08M | 332.07M | 311.88M | 287.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 346.27M | 347.08M | 332.07M | 311.88M | 287.59M |
| Cost of Revenue | 65.80M | 62.69M | 60.21M | 56.45M | 52.16M |
| Gross Profit | 280.47M | 284.39M | 271.86M | 255.43M | 235.43M |
| SG&A Expenses | 217.15M | 210.17M | 200.05M | 194.17M | 188.29M |
| Depreciation & Amortization | 36.90M | 37.18M | 11.11M | 9.04M | 9.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 369.32M | 360.87M | 323.40M | 312.92M | 303.35M |
| Operating Income | -23.05M | -13.79M | 8.67M | -1.04M | -15.76M |
| Income Before Tax | -10.25M | -2.22M | 21.56M | 11.14M | -4.02M |
| Income Tax Expenses | -781.00K | 2.85M | 3.32M | 5.06M | -918.00K |
| Earnings from Continuing Operations | -9.47 | -5.07 | 18.25 | 6.08 | -3.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.47M | -5.07M | 18.25M | 6.08M | -3.10M |
| EBIT | -23.05M | -13.79M | 8.67M | -1.04M | -15.76M |
| EBITDA | 19.44M | 28.63M | 24.67M | 12.42M | -2.67M |
| EPS Basic | -0.32 | -0.16 | 0.65 | 0.22 | -0.12 |
| Normalized Basic EPS | -0.22 | -0.02 | 0.47 | 0.25 | -0.10 |
| EPS Diluted | -0.36 | -0.20 | 0.61 | 0.20 | -0.14 |
| Normalized Diluted EPS | -0.24 | -0.04 | 0.44 | 0.23 | -0.10 |
| Average Basic Shares Outstanding | 113.49M | 112.22M | 111.10M | 110.00M | 109.00M |
| Average Diluted Shares Outstanding | 117.76M | 116.95M | 115.82M | 112.65M | 110.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |